ESR1 and breast carcinoma: Recently, Denkert et al. [45] found mutational signatures linked to HRD and APOBEC activity to be predictive of pCR after neoadjuvant chemotherapy in estrogen receptor (ER)-positive, HER2-negative, but not in ER-negative, breast cancers.